FDA Peptide Vote: What Happened in July 2026

In July 2026, an FDA advisory committee reviewed seven peptides for possible use in pharmacy compounding and recommended six of them move forward. Here’s how the committee voted, why the results matter, and what still needs to happen before anything changes for patients.

By The Vigilant German Shepherd · Published 2026-08-12T14:15:00.000Z

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee, or PCAC for short, met to review seven peptides for possible future use in pharmacy compounding. Six of the sevent received favorable recommendations from the committee, including BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. Emideltide was the only one to receive an unfavorable recommendation.

For Rex, this was an important meeting and a meaningful step in what could come next for the peptide market. For you, the reader, it may eventually affect how some of these peptides are accessed or prescribed through licensed providers and compounding pharmacies. In the sections below, we’ll dig more into the two-day meeting, discuss the seven peptides involved, and elaborate on why the results mattered and what could happen next.

Before We Get Into the Votes

The FDA and PCAC Are NOT the Same Thing.

The FDA is the federal agency that ultimately decides what action to take. PCAC is an advisory committee that reviews the available information, discusses the issue, and makes a recommendation to the FDA.

So, while the votes we’re about to discuss are important, they are only recommendations. The FDA still has to decide what happens next.

What Does It Mean for a Peptide to Be Compounded?

So, what does compounding actually mean? Instead of a drug being mass-produced in one standard version, a licensed compounding pharmacy prepares it based on a prescription for an individual patient. That can include things like the dose, strength, or form prescribed by their provider.

So, if the FDA approves the six peptides for addition to the compounding list, compounding pharmacies could make those peptides for patients who receive a prescription from a licensed provider.

What’s the Difference between FDA-Approved and Compounded?

An FDA-approved drug has gone through the FDA’s full review process. The FDA reviews the specific drug for safety, effectiveness, quality, manufacturing, dosing, and other factors before approving it for use.

A compounded drug can also be legally prescribed, but the finished medication does not go through that same FDA approval process. The FDA does not review each compounded drug for safety, effectiveness, or quality before it reaches patients.

So why use a compounded medication? Compounding gives licensed providers and pharmacies another option when an FDA-approved product does not meet a patient’s needs or, as with the peptides discussed here, when a substance is permitted for use in compounding even though there is not an FDA-approved version of that drug.

In simple terms, both FDA-approved and compounded drugs can be prescribed. The difference is the level of FDA review behind the drug before it reaches the patient.\

FDA-approved and compounded drugs can both be prescribed, but compounded drugs do not go through the same FDA approval process.

Why This Meeting Mattered?

This wasn’t the first time PCAC had reviewed a peptide for possible pharmacy compounding. What made this meeting significantly different was the seven peptides being discussed. Several, including BPC-157, TB-500, MOTS-c, and Semax, had already developed significant followings among people interested in recovery, longevity, energy, focus, and other potential benefits.

The problem was that interest had grown faster than the available human research and the regulated ways people could access them. Many people were already seeking these peptides through online sources, while the FDA continued to raise concerns about limited clinical evidence, safety, product quality, and whether some of these peptides could be consistently prepared by compounding pharmacies.

That put a pretty important question in front of PCAC: Should people have a regulated path to these peptides through licensed providers and pharmacies despite the limitations in the research, OR should access wait until stronger evidence is available?

Over the two-day meeting, PCAC reviewed the available research, heard presentations and public comments, discussed each of the seven peptides, and ultimately made a recommendation on each one.

A Look at the Two-Day Meeting

With that context in mind, here’s how the two days played out and what PCAC ultimately recommended for each of the seven peptides.

Day 1 - July 23, 2026

Day 1 covered BPC-157, KPV, TB-500, and MOTS-c. All four ultimately received favorable recommendations, although the votes were close and the committee remained divided over whether the available evidence was strong enough to support their use in pharmacy compounding.

BPC-157

BPC-157 is commonly discussed in connection with injury recovery, tissue repair, and digestive health, particularly among athletes and active adults. Interest in the peptide has grown quickly, but many of the benefits discussed online have not yet been confirmed through strong, large-scale human studies.

That lack of human evidence was one of the biggest concerns during PCAC’s review. Supporters argued that people were already seeking BPC-157 through less-regulated online sources and that allowing access through licensed providers and pharmacies could offer more oversight. Other committee members felt the available evidence was still too limited to support moving forward.

The result: 8 votes in favor, 6 against, and 1 abstention.

KPV

KPV has been studied mainly for its potential role in inflammation and is often discussed in connection with skin and gut-related concerns. Compared with BPC-157, it is less widely known, and the available human research is still limited.

The debate was similar. Some committee members supported creating a regulated path for access, while others were concerned that a favorable recommendation could be interpreted as stronger evidence of safety and effectiveness than currently exists.

The result: 8 votes in favor, 6 against, and 1 abstention.

TB-500

TB-500 is commonly discussed in connection with soft-tissue recovery, wound healing, and mobility. It has attracted particular attention among people dealing with muscle, tendon, and ligament injuries.

FDA staff raised concerns about the lack of human clinical data and the unanswered questions around safety and product quality. Even with those concerns, a majority of PCAC members supported moving it forward for possible pharmacy compounding.

The result: 8 votes in favor, 6 against, and 1 abstention.

MOTS-c

MOTS-c has been studied in connection with metabolism, insulin resistance, obesity, muscle function, and longevity. It is often discussed for its potential role in how the body uses energy, although the research in people is still early.

FDA staff again raised concerns about the limited human evidence, along with questions around testing, impurities, and whether injectable preparations could be made consistently.

The result: 7 votes in favor, 5 against, and 2 abstentions.

Day 2 - July 24, 2026

Day 2 covered Emideltide, Epitalon, and Semax. Unlike Day 1, not every peptide received a favorable recommendation. Emideltide became the only one of the seven peptides reviewed over the two days that PCAC did not recommend moving forward.

Emideltide

Emideltide, sometimes referred to as DSIP, has been discussed for potential uses related to sleep, opioid withdrawal, and narcotic dependence.

During the review, committee members raised concerns about the limited evidence supporting its effectiveness, uncertainty around the substance itself, and the fact that FDA-approved treatments already exist for some of the conditions it has been proposed to address.

The result: 6 votes in favor, 7 against, and 1 abstention.

That made Emideltide the only peptide of the seven to receive an unfavorable recommendation.

Epitalon

Epitalon is most commonly associated with longevity and anti-aging, although the research supporting many of those claims is still early. During the meeting, supporters focused more specifically on its potential use for insomnia rather than the broader longevity claims often associated with the peptide.

Other committee members remained concerned about the limited safety data, how well the substance has been studied and characterized, and possible long-term risks.

The result: 7 votes in favor, 5 against, and 1 abstention.

Despite the concerns, Epitalon received a favorable recommendation.

Semax

Semax is a synthetic peptide commonly discussed in connection with focus, memory, and brain health. It is generally delivered as a nasal spray and has been used medically in Russia for certain neurological conditions.

FDA staff recommended against adding Semax to the compounding list, pointing to limited evidence of effectiveness, unresolved safety questions, and concerns about the quality and consistency of compounded preparations.

PCAC ultimately went in a different direction, with a majority of the committee supporting Semax for possible pharmacy compounding.

The result: 8 votes in favor and 5 against.

With Semax receiving a favorable recommendation, the two-day meeting ended with six of the seven peptides receiving support from PCAC.

Summary

PCAC gave favorable recommendations to six of the seven peptides reviewed. Emideltide was the only peptide to receive an unfavorable recommendation.

What Happens Next?

The six favorable recommendations, combined with Secretary Kennedy’s support for broader access, are an important step, but they don’t immediately change how peptides are accessed. If the FDA decides to move forward, it would still need to go through its formal process before making a final decision. The FDA also does not have to follow PCAC’s recommendations.

From a timeline perspective, that’s still open-ended. The formal process can take months, but there is also pressure from the current administration to expand peptide access, which could push things along faster. FDA-watchers have also suggested the agency could introduce a temporary policy allowing compounding while the longer rulemaking process continues, although the FDA has not announced anything like that yet.

For Rex, and for anyone interested in accessing these peptides through licensed providers and pharmacies, the July votes are an encouraging step forward. But for now, they are still just that: a step forward. Until the FDA takes further action, the votes themselves do not change which of these peptides can legally be compounded.